0001171843-26-005671 | 6-K | XBRL Viewer

Note 9 - Financial Income and Expenses - Components of Financial Income and Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Statement Line Items [Line Items]
Change in fair value of derivative liability	$ 56	$ 308	$ 141	$ 2,722
Change in fair value of derivative liability	$ 0	$ (654)	$ 0	$ (724)

Note 8 - Share-based Payments (Details Textual)	6 Months Ended
Jun. 30, 2026	Jun. 30, 2025
Statement Line Items [Line Items]
Share based compensation, expiration period (Year)	10 years
Percentage of total equity	3.10%	4.30%

Label	Element	Value
evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability	evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability	$ (0)
evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability	evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability	2,432,000
evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability	evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability	(0)
evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability	evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability	(0)
evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability	evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability	(0)
evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability	evax_NoncashEffectFromIssueOfInvestorWarrantsClassifiedAsDerivativeLiability	2,432,000
Forfeited warrants	evax_ClassOfWarrantsOrRightsForfeitedInPeriodValue	0
Forfeited warrants	evax_ClassOfWarrantsOrRightsForfeitedInPeriodValue	207,000
Forfeited warrants	evax_ClassOfWarrantsOrRightsForfeitedInPeriodValue	(207,000)
Forfeited warrants	evax_ClassOfWarrantsOrRightsForfeitedInPeriodValue	0
Forfeited warrants	evax_ClassOfWarrantsOrRightsForfeitedInPeriodValue	0
Forfeited warrants	evax_ClassOfWarrantsOrRightsForfeitedInPeriodValue	0
Reclassification SBC reserve	evax_ReclassificationOfStockBasedCompensationReserve	0
Reclassification SBC reserve	evax_ReclassificationOfStockBasedCompensationReserve	4,145,000
Reclassification SBC reserve	evax_ReclassificationOfStockBasedCompensationReserve	(4,145,000)
Reclassification SBC reserve	evax_ReclassificationOfStockBasedCompensationReserve	0
Reclassification SBC reserve	evax_ReclassificationOfStockBasedCompensationReserve	0
Reclassification SBC reserve	evax_ReclassificationOfStockBasedCompensationReserve	0
Tax credit schemes accounted for as grants	evax_TaxCreditSchemesAccountedForAsGrants	0
Tax credit schemes accounted for as grants	evax_TaxCreditSchemesAccountedForAsGrants	(2,000)
Exchange rate translation effects on working capital	evax_EffectOfExchangeRateTranslationEffectsOnWorkingCapital	52,000
Exchange rate translation effects on working capital	evax_EffectOfExchangeRateTranslationEffectsOnWorkingCapital	25,000
Payment of non-current financial assets – leasehold deposits	evax_ProceedsFromPaymentsForFinancialAssets	(4,000)
Payment of non-current financial assets – leasehold deposits	evax_ProceedsFromPaymentsForFinancialAssets	$ (3,000)

Note 12 - Events After the Reporting Period (Details Textual)	Aug. 19, 2026 $ / shares shares
Statement Line Items [Line Items]
Shares issued, price per share (in dollars per share)	$ 0.25
Number of ordinary shares issued per ADS sold (in shares) \| shares	50
Shares issued, average price per share (in dollars per share)	$ 3.1533

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2026
Document Information [Line Items]
Entity Central Index Key	0001828253
Entity Registrant Name	Evaxion A/S
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2026
Document Type	6-K
Document Period End Date	Jun. 30, 2026
Entity File Number	001-39950
Entity Address, Address Line One	Dr. Neergaards Vej 5f
Entity Address, Postal Zip Code	DK-2970
Entity Address, City or Town	Hørsholm
Entity Address, Country	DK

Note 1 - General Company Information

6 Months Ended

Jun. 30, 2026

Statement Line Items [Line Items]

Description of nature of entity's operations and principal activities [text block]

Note 1. General company information

Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of 40+ experts covers the entire value chain from target discovery to clinical development.

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

Unless the context otherwise requires, references to the “Company,” “Evaxion,” “we,” “us,” and “our”, refer to Evaxion A/S and its subsidiaries.

Evaxion is a public limited liability company incorporated and domiciled in Denmark with its registered office located at Dr. Neergaards Vej 5F, DK-2970 Hørsholm, Denmark.

The unaudited condensed consolidated interim financial statements of Evaxion A/S and its subsidiaries (collectively, the “Group”) for the three and six months ended June 30, 2026, and 2025, were approved, and authorized for issuance, by the Board of Directors on August 19, 2026.

Note 7 - Borrowings (Details Textual) € in Millions	1 Months Ended	12 Months Ended
Note 7 - Borrowings (Details Textual) € in Millions	Oct. 31, 2020 m²	Dec. 31, 2021	Jul. 11, 2025 $ / shares	Jul. 11, 2025 EUR (€)	May 27, 2025 kr / shares	May 26, 2025 $ / shares
Statement Line Items [Line Items]
Lease, area (Square Metre)	1,357
Borrowings, term (Year)	8 years	6 years
Debt conversion, amount converted \| €				€ 3.5
Class of warrant, exercise price of warrants (in dollars per share) \| (per share)			$ 4.87		kr 19.15	$ 2.71
Premium of share price				89.00%
Horsholm, Denmark office space [member]
Statement Line Items [Line Items]
Lease, area (Square Metre)	839
Horsholm, Denmark laboratory space [member]
Statement Line Items [Line Items]
Lease, area (Square Metre)	518

Note 9 - Financial Income and Expenses (Tables)

6 Months Ended

Jun. 30, 2026

Statement Line Items [Line Items]

Financial income and expenses [text block]

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2026			2025			2026			2025
Financial income:
Interest income, bank	$	31		$	30		$	57		$	59
Interest income, other		—			—			—			50
Foreign exchange gains		60			208			207			208
Change in fair value of derivative liability		56			308			141			2,722
Total financial income		147			546			405			3,039
Financial expenses:
Interest expenses		(125	)		(202	)		(252	)		(391	)
Interest expenses, lease liabilities		(36	)		(39	)		(72	)		(75	)
Change in fair value of derivative liability		(-	)		(654	)		(-	)		(724	)
Foreign exchange losses		(73	)		(337	)		(195	)		(439	)
Total financial expenses		(234	)		(1,232	)		(519	)		(1,629	)
Net financial items	$	(87	)	$	(686	)	$	(114	)	$	1,410

Note 2 - Liquidity and Going Concern Assessment (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2026	Dec. 10, 2025
Statement Line Items [Line Items]
Shares outstanding, price per share (in dollars per share)		$ 11.01
Purchase agreement, maximum aggregate amount	$ 45,520

Note 5 - Revenue (Details Textual) $ in Millions	Jun. 30, 2025 USD ($)
Statement Line Items [Line Items]
Grant	$ 0.1